TLC Earns Highest Ranking in Corporate Governance Evaluation Seven Years Running
TLC has been recognized as a leader in corporate governance, ranking in the Top 5% among all Taiwan Stock Exchange and Taipei Exchange listed companies for the seventh consecutive year. This achievement underscores TLC's commitment to high standards in governance practices, particularly notable as it is the only biotech firm to secure this honor. Additionally, TLC ranks in the Top 5% of small and medium-sized enterprises with a market value of TWD 5-10 billion. The recognition will be honored at an award ceremony in June, alongside other top performers.
- Ranked in the Top 5% for corporate governance for seven consecutive years.
- Only biotech company recognized in the Top 5% category.
- Included in the Top 5% of SMEs with market value of TWD 5-10 billion.
- None.
Praised as benchmark for small and medium-sized enterprises
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 03, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it once again ranks in the Top
The 7th Corporate Governance Evaluation indicators and evaluation results can be found on the website of Corporate Governance Center at https://cgc.twse.com.tw/evaluationCorp/listEn and the Securities and Futures Institute website (https://www.sfi.org.tw/cga/cga1), with links to the Market Observation Post System (https://mops.twse.com.tw/mops/web/index) for convenient access by investors.
As customary, TWSE and TPEx will hold an award ceremony in early June to honor the Top
The 7th Corporate Governance Evaluation included 905 TWSE- and 712 TPEx-listed companies. According to the evaluation scores, the companies are divided into seven groups of the top
About TLC
TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage, specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™), including BioSeizer® sustained release technology and NanoX™ active drug loading technology, which are versatile in the choice of active pharmaceutical ingredients and scalable in manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics targeting areas of unmet medical need in pain management, ophthalmology, oncology and infectious diseases. TLC is consistently ranked in the top
FAQ
What corporate governance ranking did TLC achieve in 2021?
How many years has TLC been in the Top 5% for corporate governance?
What is TLC's market value category in the Corporate Governance Evaluation?
Who will honor TLC for its corporate governance achievements?